Skip to main content
OpenTrials
Completed

NCT Number: NCT00861484

Proof of Mechanism in ELT

The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Verona, Veneto, 37134, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation
  • Baseline Ejaculation Latency time < 3 minutes
  • Subjects must agree to use a contraception methods as per protocol
  • Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2
  • Subject with normal visual acuity (with appropriate correction if needed)
  • Subject able to cooperate in all study procedure including the eye examination with use of mydriatics

Exclusion criteria

  • Erectile dysfunction
  • History of migraine
  • Current clinically relevant abnormality
  • History of psychiatric illness or suicidal attempts or behaviours
  • History of any eye disorder or colour blind, excluding myopia and presbyopia
  • Cardiac conduction disorder or other clinically significant cardiac disease
  • Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests
  • Regular consumption of alcohol
  • History of sensitivity or intolerance to drugs
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication
  • Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication
  • Participation in another clinical trial in the previous month
  • Exposure to more than four new experimental drugs within the previous 12 months
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Unwillingness or inability to follow the procedures outlined in the protocol.

Treatment and study plan

GSK958108

Drug

Coated Tablets 1 mg

Placebo

Drug

Coated tablets

Primary outcomes

  1. Time to achieve ejaculation from the start of masturbation during audio-video erotic stimuli

    Time frame: 50 minutes

Secondary outcomes

  1. Safety and tolerability measured as adverse events occurrence, vital signs variations, safety laboratory, eye assessments, ECG and physical examination

    Time frame: 8 weeks

  2. Blood concentration of GSK958108 at different timepoints

    Time frame: From predose to 30 hours post-dose

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation

Acronym: PoM

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Mar 13, 2009
Registry last updated
Jun 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.